Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease

Authors Franssen FME, Spruit MA, Wouters EFM

Published 26 September 2011 Volume 2011:6 Pages 493—501


Review by Single-blind

Peer reviewer comments 4

Frits ME Franssen1, Martijn A Spruit1, Emiel FM Wouters1,2
1Program Development Center, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; 2Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Background: Polypharmacy of respiratory medications is commonly observed in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate determinants of polypharmacy and to study the consistency of actual respiratory drug use with current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in pulmonary rehabilitation candidates with COPD.
Methods: Data were extracted from the records of all patients with a diagnosis of COPD referred for pulmonary rehabilitation to CIRO+ between 2005 and 2009. Use of respiratory medications, self-reported COPD exacerbations, lung function, blood gases, exercise capacity, Medical Research Council (MRC) dyspnea grade, and St George’s Respiratory Questionnaire (SGRQ) were recorded as part of assessment of health status.
Results: In total, 1859 COPD patients of mean age (± standard deviation) 64.3 ± 9.7 years and with a forced expiratory volume in one second (FEV1) of 44.7% ± 18.2% were included. On average, patients used 3.5 ± 1.5 respiratory medications; this number increased with increasing GOLD stage, MRC score, and SGRQ scores. FEV1 (% predicted), SGRQ, and number of recent exacerbations were independent determinants of polypharmacy. Use of long-acting bronchodilators and inhaled corticosteroids was substantial and comparable in all GOLD stages. Use of corticosteroids was not restricted to patients with frequent exacerbations.
Conclusion: Polypharmacy of respiratory medications is common in COPD patients with persistent symptoms. In addition to severity of disease, health status is an independent predictor of polypharmacy. Actual drug use in COPD patients referred for pulmonary rehabilitation is partially inconsistent with current GOLD guidelines.

Keywords: chronic obstructive pulmonary disease, management, pharmacotherapy, polypharmacy, pulmonary rehabilitation, respiratory drug use

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Readers of this article also read:

Gold nanorods/mesoporous silica-based nanocomposite as theranostic agents for targeting near-infrared imaging and photothermal therapy induced with laser

Liu Y, Xu M, Chen Q, Guan G, Hu W, Zhao X, Qiao M, Hu H, Liang Y, Zhu H, Chen D

International Journal of Nanomedicine 2015, 10:4747-4761

Published Date: 28 July 2015

Sustained release of VH and rhBMP-2 from nanoporous magnesium–zinc–silicon xerogels for osteomyelitis treatment and bone repair

Li FQ, Wu W, Xiang L, Weng G, Hong H, Jiang H, Qian J

International Journal of Nanomedicine 2015, 10:4071-4080

Published Date: 22 June 2015

Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies

Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J

Neuropsychiatric Disease and Treatment 2015, 11:1121-1130

Published Date: 22 April 2015

Factors associated with group bullying and psychopathology in elementary school students using child-welfare facilities

Kim JW, Lee K, Lee YS, Han DH, Min KJ, Song SH, Park GN, Lee JY, Kim JO

Neuropsychiatric Disease and Treatment 2015, 11:991-998

Published Date: 7 April 2015

Study of antitumor activity in breast cell lines using silver nanoparticles produced by yeast

Ortega FG, Fernández-Baldo MA, Fernández JG, Serrano MJ, Sanz MI, Diaz-Mochón JJ, Lorente JA, Raba J

International Journal of Nanomedicine 2015, 10:2021-2031

Published Date: 16 March 2015

Kinematic analysis of motor strategies in frail aged adults during the Timed Up and Go: how to spot the motor frailty?

Hassani A, Kubicki A, Brost V, Mourey F, Yang F

Clinical Interventions in Aging 2015, 10:505-513

Published Date: 26 February 2015

Self-assembling surfactant-like peptide A6K as potential delivery system for hydrophobic drugs

Chen Y, Tang C, Zhang J, Gong M, Su B, Qiu F

International Journal of Nanomedicine 2015, 10:847-858

Published Date: 23 January 2015

Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells

Cui FB, Liu Q, Li RT, Shen J, Wu PY, Yu LX, Hu WJ, Wu FL, Jiang CP, Yue GF, Qian XP, Jiang XQ, Liu BR

International Journal of Nanomedicine 2014, 9:2345-2358

Published Date: 13 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010